Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The company ditches lorigerlimab in prostate cancer.
The response rate jumps to 30% with higher doses of IMA402.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
After more discontinuations, a new deal brings in fresh blood.
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
